IP Library Granted Patent US 9,902,759
Granted Patent B2
US 9,902,759 · App. 15/073,356 · Granted Feb 27, 2018

BH3 peptides and methods of use thereof

Inventors: Stanley J. Korsmeyer (Weston, MA); Anthony Letai (Medfield, MA)
Assignee: Dana-Farber Cancer Institute, Inc.
C07K14/4747C07K2319/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,902,759
App. No.
15/073,356
Granted
Feb 27, 2018
Kind
B2
Abstract

The invention provides peptides and the nucleic acid sequences that encode them. The invention further provides therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of apoptosis associated disorders.

Claims (8)

1. A composition for detecting homo-oligomerization of a BAX or a BAK protein in a mitochondrial membrane comprising a synthetic or recombinant BH3 peptide comprising SEQ ID NO: 2 , and a mitochondrion comprising a BAX or a BAK protein and overexpressing a BCL-2 or BCL-XL protein, wherein the BH3 peptide is less than or equal to 50 amino acids in length, and wherein the BH3 peptide forms a complex with BCL-2 or BCL-XL protein resident on the mitochondrion and activates pro-apoptotic BAX or BAK when displaced from the complex to thereby induce homo-oligomerization of the BAX or the BAK protein in the mitochondrial membrane.

2. The composition of claim 1 , wherein the mitochondrion is isolated from a cell.

3. The composition of claim 1 , wherein the BH3 peptide is less than or equal to 35 amino acids in length.

4. The composition of claim 1 , wherein the BH3 peptide is less than or equal to 25 amino acids in length.

5. A composition for detecting homo-oligomerization of a BAX or a BAK protein in a mitochondrial membrane comprising a mitochondrion contacted with a synthetic or recombinant BH3 peptide comprising SEQ ID NO: 2, wherein the mitochondrion comprises a BAX or a BAK protein and overexpresses a BCL-2 or BCL-XL protein, and wherein the BH3 peptide is less than or equal to 50 amino acids in length, and wherein the BH3 peptide forms a complex with BCL-2 or BCL-XL protein resident on the mitochondrion and activates pro-apoptotic BAX or BAK when displaced from the complex to thereby induce homo-oligomerization of the BAX or the BAK protein in the mitochondrial membrane.

6. The composition of claim 5 , wherein the mitochondrion is isolated from a cell.

7. The composition of claim 5 , wherein the BH3 peptide is less than or equal to 35 amino acids in length.

8. The composition of claim 5 , wherein the BH3 peptide is less than or equal to 25 amino acids in length.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2017
From: LETAI, ANTHONY
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 041336/0096 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2017
From: KORSMEYER, STANLEY J.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 041340/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2017
From: HOWARD HUGHES MEDICAL INSTITUTE
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 041340/0011 →
CONFIRMATORY LICENSE Recorded Dec 2, 2016
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040798/0116 →
Continuity (6)
Continuation 12966821 · Dec 13, 2010
Continuation 11789557 · Apr 24, 2007
Continuation 10658028 · Sep 9, 2003
Provisional Application 60495036 · Aug 14, 2003
Provisional Application 60409488 · Sep 9, 2002
Related Publication 20160200786A1 · Jul 14, 2016